Literature DB >> 18501608

Intraspinal hemangioblastoma: analysis of 22 cases.

S Dwarakanath1, B S Sharma, A K Mahapatra.   

Abstract

Hemangioblastomas of the spinal cord are relatively uncommon benign tumors. The purpose of this study was to evaluate the clinical features, management strategies and outcomes in patients with spinal hemangioblastomas. We retrospectively analyzed 22 patients who were operated on for spinal hemangioblastoma at the All India Institute of Medical Sciences, New Delhi, India. In our center, 113 patients with hemangioblastomas had been managed over a 14-year period (1992-2006). Ninety-one of these hemangioblastomas were intracranial and 22 were intraspinal. The average age of patients was 35.9 years. The most common location was the cervical region. The most common presenting feature was progressive compressive myelopathy (22 patients). An associated syrinx was seen in 87% of cases. Gross total resection was achieved in all patients. All but two improved or stabilized with respect to their preoperative neurological status. This is one of the larger series in the literature on spinal hemangioblastoma. We discuss the modes of presentation, surgical management strategies and excellent functional outcome after microsurgical excision.

Entities:  

Mesh:

Year:  2008        PMID: 18501608     DOI: 10.1016/j.jocn.2007.04.014

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  2 in total

Review 1.  Spinal hemangioblastoma: surgical procedures, outcomes and review of the literature.

Authors:  Huanyu Wang; Liping Zhang; Hong Wang; Yang Nan; Quanfeng Ma
Journal:  Acta Neurol Belg       Date:  2020-07-07       Impact factor: 2.396

2.  Spinal cord hemangioblastomas in von hippel-lindau disease: management of asymptomatic and symptomatic tumors.

Authors:  Tae Yup Kim; Do Heum Yoon; Hyun Chul Shin; Keung Nyun Kim; Seong Yi; Jae Keun Oh; Yoon Ha
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.